NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
These trials did not support the use of levetiracetam or zonisamide as first-line treatments in focal epilepsy or levetiracetam for newly diagnosed generalised epilepsy at 12 months.
Abstract
Background:
Levetiracetam (Keppra®, UCB Pharma Ltd, Slough, UK) and zonisamide (Zonegran®, Eisai Co. Ltd, Tokyo, Japan) are licensed as monotherapy for focal epilepsy, and levetiracetam is increasingly used as a first-line treatment for generalised epilepsy, particularly for women of childbearing age. However, there is uncertainty as to whether or not they should be recommended as first-line treatments owing to a lack of evidence of clinical effectiveness and cost-effectiveness.
Objectives:
To compare the clinical effectiveness and cost-effectiveness of lamotrigine (Lamictal®, GlaxoSmithKline plc, Brentford, UK) (standard treatment) with levetiracetam and zonisamide (new treatments) for focal epilepsy, and to compare valproate (Epilim®, Sanofi SA, Paris, France) (standard treatment) with levetiracetam (new treatment) for generalised and unclassified epilepsy.
Design:
Two pragmatic randomised unblinded non-inferiority trials run in parallel.
Setting:
Outpatient services in NHS hospitals throughout the UK.
Participants:
Those aged ≥ 5 years with two or more spontaneous seizures that require anti-seizure medication.
Interventions:
Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide. Participants with generalised or unclassifiable epilepsy were randomised to receive valproate or levetiracetam. The randomisation method was minimisation using a web-based program.
Main outcome measures:
The primary outcome was time to 12-month remission from seizures. For this outcome, and all other time-to-event outcomes, we report hazard ratios for the standard treatment compared with the new treatment. For the focal epilepsy trial, the non-inferiority limit (lamotrigine vs. new treatments) was 1.329. For the generalised and unclassified epilepsy trial, the non-inferiority limit (valproate vs. new treatments) was 1.314. Secondary outcomes included time to treatment failure, time to first seizure, time to 24-month remission, adverse reactions, quality of life and cost-effectiveness.
Results:
Focal epilepsy. A total of 990 participants were recruited, of whom 330 were randomised to receive lamotrigine, 332 were randomised to receive levetiracetam and 328 were randomised to receive zonisamide. Levetiracetam did not meet the criteria for non-inferiority (hazard ratio 1.329) in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio vs. lamotrigine 1.18, 97.5% confidence interval 0.95 to 1.47), but zonisamide did meet the criteria (hazard ratio vs. lamotrigine 1.03, 97.5% confidence interval 0.83 to 1.28). In the per-protocol analysis, lamotrigine was superior to both levetiracetam (hazard ratio 1.32, 95% confidence interval 1.05 to 1.66) and zonisamide (hazard ratio 1.37, 95% confidence interval 1.08 to 1.73). For time to treatment failure, lamotrigine was superior to levetiracetam (hazard ratio 0.60, 95% confidence interval 0.46 to 0.77) and zonisamide (hazard ratio 0.46, 95% confidence interval 0.36 to 0.60). Adverse reactions were reported by 33% of participants starting lamotrigine, 44% starting levetiracetam and 45% starting zonisamide. In the economic analysis, both levetiracetam and zonisamide were more costly and less effective than lamotrigine and were therefore dominated. Generalised and unclassifiable epilepsy. Of 520 patients recruited, 260 were randomised to receive valproate and 260 were randomised to receive to levetiracetam. A total of 397 patients had generalised epilepsy and 123 had unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the primary intention-to-treat analysis of time to 12-month remission (hazard ratio 1.19, 95% confidence interval 0.96 to 1.47; non-inferiority margin 1.314). In the per-protocol analysis of time to 12-month remission, valproate was superior to levetiracetam (hazard ratio 1.68, 95% confidence interval 1.30 to 2.15). Valproate was superior to levetiracetam for time to treatment failure (hazard ratio 0.65, 95% confidence interval 0.50 to 0.83). Adverse reactions were reported by 37.4% of participants receiving valproate and 41.5% of those receiving levetiracetam. Levetiracetam was both more costly (incremental cost of £104, 95% central range –£587 to £1234) and less effective (incremental quality-adjusted life-year of –0.035, 95% central range –0.137 to 0.032) than valproate, and was therefore dominated. At a cost-effectiveness threshold of £20,000 per quality-adjusted life-year, levetiracetam was associated with a probability of 0.17 of being cost-effective.
Limitations:
The SANAD II trial was unblinded, which could have biased results by influencing decisions about dosing, treatment failure and the attribution of adverse reactions.
Future work:
SANAD II data could now be included in an individual participant meta-analysis of similar trials, and future similar trials are required to assess the clinical effectiveness and cost-effectiveness of other new treatments, including lacosamide and perampanel.
Conclusions:
Focal epilepsy – The SANAD II findings do not support the use of levetiracetam or zonisamide as first-line treatments in focal epilepsy. Generalised and unclassifiable epilepsy – The SANAD II findings do not support the use of levetiracetam as a first-line treatment for newly diagnosed generalised epilepsy. For women of childbearing potential, these results inform discussions about the benefit (lower teratogenicity) and harm (worse seizure outcomes and higher treatment failure rate) of levetiracetam compared with valproate.
Trial registration:
Current Controlled Trials ISRCTN30294119 and EudraCT 2012-001884-64.
Funding:
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 75. See the NIHR Journals Library website for further project information.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Introduction
- Chapter 2. Trial design and methods
- Study design
- Study sites
- Participants
- Recruitment procedure
- Informed consent
- Randomisation, concealment and blinding
- Treatment group allocation
- Data collection and management
- Baseline assessment
- Follow-up
- Outcome measures
- Sample size
- Statistical analysis
- Health economics
- Patient and public involvement
- Protocol amendments
- Trial funder
- Trial co-sponsors
- Trial management and quality assurance
- Trial oversight
- Ethics considerations, regulatory requirements and research governance framework
- Chapter 3. Focal epilepsy: clinical results
- Chapter 4. Focal epilepsy results: economic
- Chapter 5. Focal epilepsy: discussion
- Chapter 6. Generalised and unclassified epilepsy: clinical results
- Chapter 7. Generalised and unclassified epilepsy results: economic
- Chapter 8. Generalised and unclassified epilepsy: discussion
- Acknowledgements
- References
- Appendix 1. Trial sites and principal investigators
- Appendix 2. Key protocol amendments
- Appendix 3. Further details of results
- Appendix 4. Additional tables and figures for the health economic analysis
- List of abbreviations
About the Series
Declared competing interests of authors: Anthony G Marson reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme during the conduct of the study, and grants from UCB (Brussels, Belgium) outside the submitted work. Graeme Sills reports personal fees from UCB, Eisai Co. Ltd (Tokyo, Japan) and Arvelle Therapeutics GmbH (Zug, Switzerland) outside the submitted work. John Leach reports grants from the University of Liverpool/HTA during the conduct of the study; personal fees from Eisai Co. Ltd; grants and personal fees from UCB; and personal fees from Janssen: Pharmaceutical Companies of Johnson & Johnson (Beerse, Belgium), GlaxoSmithKline plc (Brentford, UK) and GW Pharmaceuticals (Cambridge, UK) outside the submitted work. Philip EM Smith reports being co-editor of Practical Neurology (2011–present) and a member of the National Institute for Health and Care Excellence Guidelines Group for Epilepsy (2019–21). Rajiv Mohanraj reports personal fees from UCB, and grants from UCB and Sanofi SA (Paris, France) outside the submitted work. Catrin Tudur-Smith reports a committee membership (HTA Commissioning Committee) (2015–20). Paula R Williamson was Director of Liverpool Clinical Trials Centre (formerly Medicines for Children Clinical Trials Unit) (April 2005–December 2018), which received funding from NIHR (end date 31 August 2021). She also reports grants from the University of Liverpool and from the NIHR HTA programme during the conduct of the study.
Article history
The research reported in this issue of the journal was funded by the HTA programme as project number 09/144/09. The contractual start date was in June 2012. The draft report began editorial review in October 2020 and was accepted for publication in August 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Last reviewed: October 2020; Accepted: August 2021.
- NLM CatalogRelated NLM Catalog Entries
- Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate ...Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs
- Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous f...Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study
- Development of a cost-effectiveness model for optimisation of the screening inte...Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening
- Pharmacological and non-pharmacological treatments and outcomes for new-onset at...Pharmacological and non-pharmacological treatments and outcomes for new-onset atrial fibrillation in ICU patients: the CAFE scoping review and database analyses
- A Systematic Review and Economic Evaluation of Cilostazol, Naftidrofuryl Oxalate...A Systematic Review and Economic Evaluation of Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline and Inositol Nicotinate for the Treatment of Intermittent Claudication in People with Peripheral Arterial Disease
Your browsing activity is empty.
Activity recording is turned off.
See more...